End-stage kidney disease on haemodialysis Urological and Genital Diseases Chronic renal failure
Conditions
Interventions
For sequence 1, the patient will undergo three HD sessions with PCDs, followed by three HD sessions without PCDs. For sequence 2, the patient will undergo three HD sessions without PCDs, followed by t
the follow up period is the same.
Sponsors
University of Calgary (Canada)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Chronic stable HD patients who have been on HD at least three times per week for at least 3 months 2. Both males and females, aged 18 - 95 years
Exclusion criteria
Exclusion criteria: 1. Dialysing with a central venous catheter 2. Vascular access dysfunction 3. Lower extremity arterial ulcers, severe peripheral arterial disease, lower extremity amputations 4. Active medical issues 5. Unable to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in central blood volume with and without PCDs in both IDH-prone patients and non-IDH prone patients. Central blood volume will be determined using ultrasound dilution technique as per standard procedures. Determined within the first 30 minutes of HD and again within the last 15 minutes of the HD session; this is done for each of the study HD sessions (three with treatment, three with control). | — |
Secondary
| Measure | Time frame |
|---|---|
| Determined within the first 30 minutes of HD and again at the last 15 minutes of HD for each of the study sessions: 1. Cardiac output 2. Mean arterial pressure 3. Bioimpedance derived extracellular fluid (ECF) and intracellular fluid (ICF) values | — |
Countries
Canada
Outcome results
None listed